Targeted protein degradation (TPD) and other induced proximity modalities are established concepts in academic chemical biology that are revolutionizing drug discovery by offering a new mode of controlling protein function for therapeutic targeting. These approaches rely on the use of small molecules or other biomolecules to bring target proteins of interest in proximity with effector proteins to elicit a biological pathway (protein turnover for TPD) or therapeutic effect. This Keystone Symposia conference will showcase the latest technological innovations in induced proximity, guided by basic mechanistic insights, and will report on emerging clinical data as these modalities advance from concepts to therapeutics. Accordingly, this Keystone Symposia conference will center on methods for chemical remodeling and rewiring of proteins to control biomolecular interactions across basic and translational research. The program will highlight emerging frontiers with translational potential, including the discovery of new E3 ligases and induced proximity modalities. It will integrate advances in discovery chemistry and biology that underpin these approaches, while also exploring next-generation technologies, such as artificial intelligence, to accelerate future innovations and therapeutic discovery. Designed to foster interactions that catalyze the exchange of new ideas for drug development, the conference will assemble recognized leaders with emerging scientists who offer fresh perspectives and new approaches. By bringing together a community that spans leaders from the lab to the clinic across academia and industry, the conference will inspire new ideas and opportunities for collaborations to deliver the next wave of breakthroughs for TPD and induced proximity that will translate into non-traditional modalities for targeting disease biology in innovative ways.